# PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer

> **NCT01723800** · PHASE1 · COMPLETED · sponsor: **City of Hope Medical Center** · enrollment: 9 (actual)

## Conditions studied

- Recurrent Non-small Cell Lung Cancer
- Stage IV Non-small Cell Lung Cancer

## Interventions

- **DRUG:** PI3K inhibitor BKM120
- **DRUG:** pemetrexed disodium
- **DRUG:** carboplatin
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study
- **PROCEDURE:** quality-of-life assessment

## Key facts

- **NCT ID:** NCT01723800
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2016-09
- **Final completion:** 2016-09
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2016-09-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01723800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01723800, "PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01723800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*